Trials / Terminated
TerminatedNCT01685021
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- MorphoSys AG · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MOR00208 (formerly Xmab5574) |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2012-09-13
- Last updated
- 2018-02-22
- Results posted
- 2018-02-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01685021. Inclusion in this directory is not an endorsement.